Zap1 is required for Candida glabrata response to fluconazole

Area of Science:

• Mycology
• Molecular Biology
• Antifungal Resistance

Background:

• Fluconazole resistance in Candida species is a growing clinical challenge.
• Understanding fungal responses to antifungals is crucial for developing new therapies.

Purpose of the Study:

• To investigate the role of Zap1 in Candida glabrata's response to fluconazole.
• To elucidate the mechanisms underlying Zap1-mediated fluconazole resistance.

Main Methods:

• Gene deletion studies (CgΔzap1 mutant).
• Measurement of intracellular fluconazole accumulation.
• Analysis of ergosterol and membrane phospholipid composition.
• Gene expression analysis of drug efflux transporters (CDR1) and regulators (PDR1).

Main Results:

• Candida glabrata cells lacking Zap1 (CgΔzap1) accumulate higher levels of fluconazole.
• Zap1 deletion correlates with reduced ergosterol levels and altered membrane phospholipid composition.
• Zap1 acts as a negative regulator of the drug efflux transporter gene CDR1 and its regulator PDR1.
• Impaired membrane function in Zap1-depleted cells likely contributes to increased fluconazole sensitivity.

Conclusions:

• Zap1 plays a significant role in Candida glabrata's response to fluconazole, extending beyond zinc homeostasis.
• Zap1 influences drug accumulation and membrane integrity, impacting fluconazole efficacy.
• Targeting Zap1 or its associated pathways could offer novel strategies to combat fluconazole-resistant Candida infections.